Kevin Tang bought $12.7M of Aurinia Pharmaceuticals (AUPH)
Executed Feb 28 2025, disclosed Mar 4 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 4 2025), the stock returned +1.3% (delay-adjusted); from the execution session (Feb 28 2025), +11.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Kevin Tang (Director) filed 9 Form 4 reports in the trailing twelve months (9 purchases, 0 sales), most often in Aurinia Pharmaceuticals Inc. (AUPH). Across 8 priced purchase filings, the average 21-session return was +4.8% from execution and +6.8% from disclosure (delay-adjusted; derived). The largest single filing was $12.7M of AUPH (898,400 sh across 5 lots, as filed), executed Feb 27.
Healthcare · Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with h…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→812,208 sh across 3 lots
Exec May 29
Filed Jun 2 · 9:54 PM ET AUPHPURCHASE Aurinia Pharmaceuticals Inc. $12.7M
898,400 sh across 5 lots
Exec Feb 27
Filed Mar 3 · 5:35 PM ET AUPHPURCHASE Aurinia Pharmaceuticals Inc. $13.6M
1,300,000 sh across 3 lots
Exec Aug 1 2025
Filed Aug 5 2025 · 5:31 PM ET AUPHPURCHASE Aurinia Pharmaceuticals Inc. $10.8M
1,200,000 sh across 3 lots
Exec Dec 5 2024
Filed Dec 9 2024 · 5:30 PM ET